Short-acting β2-agonist prescriptions in patients with asthma: findings from the South Korean cohort of SABINA III
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Despite short-acting β2-agonist (SABA) overuse being associated with poor asthma outcomes, data on SABA use in South Korea is scarce. Herein, we describe prescription patterns of SABA and other asthma medications in patients from the South Korean cohort of the SABA use IN Asthma (SABINA) III study. Methods: This study included patients with asthma aged ≥ 12 years, who had ≥ 3 consultations with the same healthcare provider, and medical records containing data for ≥ 12 months prior to the study visit. Patients were classified by investigator-defined asthma severity (per 2017 Global Initiative for Asthma recommendations) and practice type (primary or specialist care). Data on disease characteristics, asthma treatments, and clinical outcomes in the 12 months before the study visit were collected using electronic case report forms. Results: Data from 476 patients (mean age, 55.4 years; female, 63.0%) were analyzed. Most patients were treated by specialists (83.7%) and had moderate-to-severe asthma (91.0%). Overall, 7.6% of patients were prescribed ≥ 3 SABA canisters (defined as over-prescription). In patients prescribed SABA in addition to maintenance therapy, 47.4% were over-prescribed SABA. Most patients (95.4%) were prescribed a fixed-dose combination of an inhaled corticosteroid and a long-acting β2-agonist as maintenance therapy. Although asthma was well-controlled/partly-controlled in 91.6% of patients, 29.6% experienced ≥ 1 severe asthma exacerbation. Conclusions: SABA over-prescription was reported in nearly 50% of patients prescribed SABA in addition to maintenance therapy, underscoring the need to align clinical practices with the latest evidence-based recommendations and educate physicians and patients on appropriate SABA use.
Abstract
Background/Aims: Despite short-acting β2-agonist (SABA) overuse being associated with poor asthma outcomes, data on SABA use in South Korea is scarce. Herein, we describe prescription patterns of SABA and other asthma medications in patients from the South Korean cohort of the SABA use IN Asthma (SABINA) III study. Methods: This study included patients with asthma aged ≥ 12 years, who had ≥ 3 consultations with the same healthcare provider, and medical records containing data for ≥ 12 months prior to the study visit. Patients were classified by investigator-defined asthma severity (per 2017 Global Initiative for Asthma recommendations) and practice type (primary or specialist care). Data on disease characteristics, asthma treatments, and clinical outcomes in the 12 months before the study visit were collected using electronic case report forms. Results: Data from 476 patients (mean age, 55.4 years; female, 63.0%) were analyzed. Most patients were treated by specialists (83.7%) and had moderate-to-severe asthma (91.0%). Overall, 7.6% of patients were prescribed ≥ 3 SABA canisters (defined as over-prescription). In patients prescribed SABA in addition to maintenance therapy, 47.4% were over-prescribed SABA. Most patients (95.4%) were prescribed a fixed-dose combination of an inhaled corticosteroid and a long-acting β2-agonist as maintenance therapy. Although asthma was well-controlled/partly-controlled in 91.6% of patients, 29.6% experienced ≥ 1 severe asthma exacerbation. Conclusions: SABA over-prescription was reported in nearly 50% of patients prescribed SABA in addition to maintenance therapy, underscoring the need to align clinical practices with the latest evidence-based recommendations and educate physicians and patients on appropriate SABA use.
참고문헌 (36)
- "The Global Asthma Report 2018" (2018)[URL]
- Lee E, "Increasing prevalence and mortality of asthma with age in Korea, 2002-2015 : a nationwide, population-based study", Allergy Asthma Immunol Res, 12, pp.467~484 (2020)
- "National health insurance statistical yearbook" (2022)[URL]
- Demoly P, "Repeated cross-sectional survey of patient-reported asthma control in Europe in the past 5 years", Eur Respir Rev, 21, pp.66~74 (2012)
- Dhar R, "Challenges faced in managing adult asthma : a perspective from Asian countries", Respirology, 25, pp.1235~1242 (2020)
- Price D, "Time for a new language for asthma control : results from REALISE Asia", J Asthma Allergy, 8, pp.93~103 (2015)
- O’Byrne PM, "The paradoxes of asthma management : time for a new approach?", Eur Respir J, 50, pp.1701103~ (2017)
- Bloom CI, "Asthma-related health outcomes associated with short-acting β2-agonist inhaler use : an observational UK study as part of the SABINA global program", Adv Ther, 37, pp.4190~4208 (2020)
- Nwaru BI, "Overuse of short-acting β2-agonists in asthma is associated with increased risk of exacerbation and mortality : a nationwide cohort study of the global SABINA programme", Eur Respir J, 55, pp.1901872~ (2020)
- "Global strategy for asthma management and prevention. 2023 update" (2023)[URL]
- "Health security system" (2020)[URL]
- Lee H, "Short-acting beta2-agonist use in asthma in Korea : a 10-year population-based study", Allergy Asthma Immunol Res, 13, pp.945~953 (2021)
- Cabrera CS, "SABINA : global programme to evaluate prescriptions and clinical outcomes related to short-acting β2-agonist use in asthma", Eur Respir J, 55, pp.1901858~ (2020)
- Janson C, "SABINA : an overview of short-acting β2-agonist use in asthma in European countries", Adv Ther, 37, pp.1124~1135 (2020)
- Bateman ED, "Short-acting β2-agonist prescriptions are associated with poor clinical outcomes of asthma : the multi-country, cross-sectional SABINA III study", Eur Respir J, 59, pp.2101402~ (2022)
- "Global strategy for asthma management and prevention. 2017 update" (2017)[URL]
- "Regional Office for the Western Pacific. The Asia-Pacific perspective: redefining obesity and its treatment" (2000)[URL]
- Reddel HK, "An official American Thoracic Society", European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice, 2009, pp.180, 59~99
- Choi JY, "Current status of asthma care in South Korea : nationwide the Health Insurance Review and Assessment Service database", J Thorac Dis, 9, pp.3208~3214 (2017)
- Jo EJ, "Implementation of asthma management guidelines and possible barriers in Korea", J Korean Med Sci, 35, pp.e72~ (2020)
- Cho EY, "Comparison of clinical characteristics and management of asthma by types of health care in South Korea", J Thorac Dis, 10, pp.3269~3276 (2018)
- "Pharmaceutical affairs acts" (2017)[URL]
- Kim S, "Healthcare use and prescription patterns associated with adult asthma in Korea : analysis of the NHI claims database", Allergy, 68, pp.1435~1442 (2013)
- Choi JY, "Nationwide use of inhaled corticosteroids by South Korean asthma patients : an examination of the Health Insurance Review and Service database", J Thorac Dis, 10, pp.5405~5413 (2018)
- Kim SR, "Current epidemiological data on asthma management in South Korea from qualitative assessment of asthma management by Health Insurance Review and Assessment Service(HIRA)", Tuberc Respir Dis(Seoul), 80, pp.221~225 (2017)
- Price D, "Short-course systemic corticosteroids in asthma : striking the balance between efficacy and safety", Eur Respir Rev, 29, pp.190151~ (2020)
- Thompson PJ, "Insights, attitudes and perceptions about asthma and its treatment : findings from a multinational survey of patients from 8 Asia-Pacific countries and Hong Kong", Respirology, 18, pp.957~967 (2013)
- Chin MC, "Prescription of oral short-acting beta 2-agonist for asthma in non-resource poor settings : a national study in Malaysia", PLoS One, 12, pp.e0180443~ (2017)
- Tan NC, "Factors influencing family physicians’ drug prescribing behaviour in asthma management in primary care", Singapore Med J, 50, pp.312~319 (2009)
- Kuna P, "Effect of budesonide", formoterol maintenance and reliever therapy on asthma exacerbations, 2007, pp.61, 725~736
- Rabe KF, "Budesonide", formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma : a randomized, double-blind trial, 2006, pp.129, 246~256
- O’Byrne PM, "Inhaled combined budesonide-formoterol as needed in mild asthma", N Engl J Med, 378, pp.1865~1876 (2018)
- Boulet LP, "Evaluation of asthma control by physicians and patients : comparison with current guidelines", Can Respir J, 9, pp.417~423 (2002)
- Baddar S, "Is clinical judgment of asthma control adequate? : a prospective survey in a tertiary hospital pulmonary clinic", Sultan Qaboos Univ Med J, 13, pp.63~68 (2013)
- Price D, "Asthma control and management in 8, 000 European patients : the REcognise Asthma and LInk to Symptoms and Experience(REALISE)survey", NPJ Prim Care Respir Med, 24, pp.14009~ (2014)
- Organisation for Economic Co-operation and Development (OECD), "OECD Reviews of Public Health: Korea. A Healthier Tomorrow" (2020), OECD Publishing